Progression-Free Survival [doba přežití bez progrese choroby]

topical
493
Terms

EFS
PFS
přežití bez příhody
přežití bez progrese nemoci
přežití bez události
přežití do progrese choroby
přežití do progrese nemoci

 

Event-Free Survival

Persistent link   https://www.medvik.cz/link/D000077982
Definition

Length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but the disease does not get worse.

DUI
D000077982 MeSH Browser
CUI
M0027838
Previous indexing
Disease-Free Survival (1995-2018)
History note
2019; use DISEASE-FREE SURVIVAL 1995-2018; for EVENT-FREE SURVIVAL use DISEASE-FREE SURVIVAL 1995-2018
Public note
2019; see DISEASE-FREE SURVIVAL 1995-2018; for EVENT-FREE SURVIVAL see DISEASE-FREE SURVIVAL 1995-2018

E Analytical, Diagnostic and Therapeutic Techniques and Equipment
E01 Diagnosis 1 790
E01.789 Prognosis 9 647
E01.789.800 Treatment Outcome 21 685
E01.789.800.190 Disease-Free Survival 1 443
E01.789.800.238 Early Termination of Clinical Trials 16
E01.789.800.262 Pathologic Complete Response 5
E01.789.800.285 Progression-Free Survival 493
E01.789.800.379 Response Evaluation Criteria in Solid Tumors 42
E01.789.800.570 Sustained Virologic Response 19
E01.789.800.665 Therapeutic Index 6
E01.789.800.713 Treatment Expectations
E01.789.800.760 Treatment Failure 668
E05 Investigative Techniques 209
E05.318 Epidemiologic Methods 1 030
E05.318.740 Statistics as Topic 13 066
E05.318.740.998 Survival Analysis 3 040
E05.318.740.998.300 Disease-Free Survival 1 443
E05.318.740.998.650 Kaplan-Meier Estimate 728
E05.318.740.998.738 Progression-Free Survival 493
E05.318.740.998.825 Proportional Hazards Models 475

N Health Care
N04 Health Services Administration 1 737
N04.761 Quality of Health Care 2 491
N04.761.559 Outcome and Process Assessment, Health Care 1 870
N04.761.559.590 Outcome Assessment, Health Care 584
N04.761.559.590.800 Treatment Outcome 21 685
N04.761.559.590.800.190 Disease-Free Survival 1 443
N04.761.559.590.800.379 Early Termination of Clinical Trials 16
N04.761.559.590.800.427 Pathologic Complete Response 5
N04.761.559.590.800.474 Progression-Free Survival 493
N04.761.559.590.800.569 Response Evaluation Criteria in Solid Tumors 42
N04.761.559.590.800.665 Sustained Virologic Response 19
N04.761.559.590.800.713 Therapeutic Index 6
N04.761.559.590.800.737 Treatment Expectations
N04.761.559.590.800.760 Treatment Failure 668
N05 Health Care Quality, Access, and Evaluation 685
N05.715 Quality of Health Care 2 491
N05.715.360 Health Care Evaluation Mechanisms 200
N05.715.360.575 Outcome and Process Assessment, Health Care 1 870
N05.715.360.575.575 Outcome Assessment, Health Care 584
N05.715.360.575.575.800 Treatment Outcome 21 685
N05.715.360.575.575.800.190 Disease-Free Survival 1 443
N05.715.360.575.575.800.379 Early Termination of Clinical Trials 16
N05.715.360.575.575.800.427 Pathologic Complete Response 5
N05.715.360.575.575.800.474 Progression-Free Survival 493
N05.715.360.575.575.800.569 Response Evaluation Criteria in Solid Tumors 42
N05.715.360.575.575.800.665 Sustained Virologic Response 19
N05.715.360.575.575.800.713 Therapeutic Index 6
N05.715.360.575.575.800.737 Treatment Effect Heterogeneity
N05.715.360.575.575.800.749 Treatment Expectations
N05.715.360.575.575.800.760 Treatment Failure 668
N05.715.360.750 Statistics as Topic 13 066
N05.715.360.750.795 Survival Analysis 3 040
N05.715.360.750.795.300 Disease-Free Survival 1 443
N05.715.360.750.795.650 Kaplan-Meier Estimate 728
N05.715.360.750.795.738 Progression-Free Survival 493
N05.715.360.750.795.825 Proportional Hazards Models 475
N06 Environment and Public Health 202
N06.850 Public Health 4 036
N06.850.520 Epidemiologic Methods 1 030
N06.850.520.830 Statistics as Topic 13 066
N06.850.520.830.998 Survival Analysis 3 040
N06.850.520.830.998.300 Disease-Free Survival 1 443
N06.850.520.830.998.650 Kaplan-Meier Estimate 728
N06.850.520.830.998.825 Progression-Free Survival 493
N06.850.520.830.998.912 Proportional Hazards Models 475

Add